Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination Crystal ZhengIndrani KarHesham Abboud Current Opinion 11 August 2020 Pages: 879 - 896
Application of Healthcare ‘Big Data’ in CNS Drug Research: The Example of the Neurological and mental health Global Epidemiology Network (NeuroGEN) Jenni IlomäkiJ. Simon BellIan C. K. Wong Leading Article 22 June 2020 Pages: 897 - 913
Enhancing the Activity of Glucocerebrosidase as a Treatment for Parkinson Disease Elisa MenozziAnthony H. V. Schapira Leading Article 01 July 2020 Pages: 915 - 923
Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies Joost J. BreeksemaAlistair R. NiemeijerRobert A. Schoevers Systematic Review Open access 17 August 2020 Pages: 925 - 946
Targeting Serotonin 5-HT2A Receptors to Better Treat Schizophrenia: Rationale and Current Approaches Joshua T. Kantrowitz Review Article 11 August 2020 Pages: 947 - 959
Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study Peter J. WeidenYangchun DuDavid P. Walling Original Research Article Open access 03 July 2020 Pages: 961 - 972
Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study Tjalf ZiemssenAnn D. BassCARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ investigators Original Research Article Open access 24 July 2020 Pages: 973 - 988
Eslicarbazepine Acetate: A Review in Focal-Onset Seizures Young-A Heo Adis Drug Evaluation 31 July 2020 Pages: 989 - 1000